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Research toward the mechanisms underlying obesity-linked complications has intensified
during the last years. As a consequence, it has become clear that metabolism and immu-
nity are intimately linked. Free fatty acids and other lipids acquired in excess by current
feeding patterns have been proposed to mediate this link due to their immune modula-
tory capacity. The functional differences between saturated and unsaturated fatty acids, in
combination with their dietary intake are believed to modulate the outcome of immune
responses. Moreover, unsaturated fatty acids can be oxidized in a tightly regulated and
specific manner to generate either potent pro-inflammatory or pro-resolving lipid media-
tors. These oxidative derivatives of fatty acids have received detailed attention during the
last years, as they have proven to have strong immune modulatory capacity, even in pM
ranges. Both fatty acids and oxidized fatty acids have been studied especially in relation to
macrophage andT-cells functions. In this review, we propose to focus on the effect of fatty
acids and their oxidative derivatives on T-cells, as it is an active area of research during the
past 5 years. The effect of fatty acids and their derivatives on activation and proliferation
of T-cells, as well as the delicate balance between stimulation and lipotoxicity will be dis-
cussed. Moreover, the receptors involved in the interaction between free fatty acids and
their derivatives withT-cells will be summarized. Finally, the mechanisms involved in modu-
lation ofT-cells by fatty acids will be addressed, including cellular signaling and metabolism
ofT-cells.The in vitro results will be placed in context of in vivo studies both in humans and
mice. In this review, we summarize the latest findings on the immune modulatory function
of lipids on T-cells and will point out novel directions for future research.
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INTRODUCTION
Obesity is increasing in the Western society, and obesity-linked
complications are under intense scrutiny. Among these, not
only metabolic disorders, such as diabetes mellitus and dyslipi-
demia, but also cardiovascular disorders, such as hypertension
and ischemic heart diseases, have been shown to be associated
with obesity (1, 2). More recently, also chronic diseases in which
inflammation plays a role such as osteoarthritis, rheumatoid
arthritis, inflammatory bowel disease, chronic obstructive pul-
monary disease, and asthma have been associated with obesity
(3–6). Likewise, evidence exists indicating a relationship between
obesity and increased susceptibility for infections (7), as well as
a lower response to vaccination (8) indicating that obesity can
impact immune responses. Although the mechanisms underlying
these associations are unclear, adipose tissue-derived inflamma-
tion could play a role in the development and progression of
these diseases. Indeed, adipose tissue serves not only as an energy
depot but it is also a highly active metabolic and endocrine organ,
affecting whole body metabolism (3, 9, 10).
The adipose tissue consists of adipocytes and the stromal vas-
cular fraction, in which a variety of immune cells can be found.
Among these, macrophages and T-cells are the most abundant
(11). Expansion of the adipose tissue is accompanied by an
increased infiltration of immune cells with a pro-inflammatory
phenotype. The cross-talk between the infiltrating cells and
the tissue-resident adipocytes leads to secretion of adipokines,
cytokines, chemokines, and lipids with a predominant pro-
inflammatory character (3, 10). Moreover, the levels of vari-
ous adipokines and cytokines are altered in obese individuals
compared to lean ones (e.g., leptin, adiponectin, IL-6) (12).
This cross-talk has also been shown to affect the function of
adipocytes, such as lipolysis, which will most likely result in an
altered concentration of circulating free fatty acids. Indeed, obese
persons have higher levels of free fatty acids in plasma compared to
lean persons (13–15). Whether and which of these soluble factors
(adipokines, cytokines, lipids, etc.) contribute to obesity-mediated
inflammatory effects in diseases is still under investigation.
Several indirect lines of evidence suggest that fatty acids can
modulate the immune response. One of these is that levels of sev-
eral fatty acids are associated with levels of inflammatory markers
in healthy individuals (16). More directly, the type of fatty acids
contained in the diet has been suggested to influence the risk of
development of inflammatory diseases in which the immune sys-
tem plays an important role. Fatty acids from animal sources, such
as meat and poultry, are mainly saturated fatty acids or omega-6
(ω6) unsaturated fatty acids, while fatty acids derived from plant-
based foods, oils, and certain types of fatty fish consist mainly
of ω3 unsaturated fatty acids. Diets rich in ω6 polyunsaturated
fatty acids (PUFAs) increase the risk of development of inflamma-
tory diseases, such as rheumatoid arthritis, inflammatory bowel
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disease, and asthma (17). On the other hand, diets rich in ω3
PUFAs seem to have anti-inflammatory effects as indicated both
by the decreased risk and the amelioration of these diseases (17–
20). Moreover, it has been shown that after in vivo challenge with
a pathogen, the host survival and pathogen clearance is affected
by diets enriched in fatty acids, although this is dependent on the
infectious agent and the fatty acids used (21, 22).
Additionally, unsaturated fatty acids can be oxidized to generate
either potent pro-inflammatory or pro-resolving lipid mediators.
These lipid mediators have strong immune modulatory capacity
and are generated in a timely and controlled manner during an
inflammatory response (23). Pro-inflammatory lipid mediators,
such as prostaglandins and leukotrienes, are produced first. When
the tissue-damaging or infectious agent is removed, the produc-
tion of pro-resolving lipid mediators associates with restoration
of normal tissue homeostasis (24).
In conclusion, several publications indicate that fatty acids and
lipid mediators derived from fatty acids can potently influence
the immune system. Although it is often unclear which cells are
responsible for the immune modulatory effects of fatty acids, these
lipids have been shown to affect the function of several immune
cells, especially antigen-presenting cells and T-cells (25, 26). In
this review, we propose to summarize the knowledge regarding
the effect of fatty acids and their oxidative derivatives on T-cells,
both in vitro and in vivo, as it has been an active area of research
during recent years.
FATTY ACIDS
Fatty acids serve not only as fuel for cells but are also components
of cell membrane phospholipids and glycolipids, and precursors of
bioactive lipid mediators (27). Fatty acids are hydrocarbon struc-
tures, which can differ in the number of carbon atoms and the
degree of saturation. Therefore, they are classified according to
length (number of carbon residues in the lipid backbone), sat-
uration, and number and position of the double bonds. Fatty
acids can be either short-chain (4–10 carbons), medium-chain
(12–14 carbons), long-chain (16–18 carbons) or very long-chain
fatty acids (20 or more carbons). In addition, these lipids can be
classified according to the presence or absence of a double bond
in the backbone. Fatty acids that do not have a double bond are
called saturated fatty acids and those having one or more double
bonds are called monounsaturated fatty acids (MUFAs) or PUFAs,
respectively. The position of the double bond determines whether
PUFAs can be characterized asω3,ω6, orω9, wherebyω indicates
the methyl end of the fatty acid and the number indicates the car-
bon counted from the methyl end that contains a double bond.
Table 1 shows an overview of fatty acids most commonly used
in literature. Some of the PUFAs, especially AA, DHA, and EPA
and their influence on the immune system have been extensively
reviewed elsewhere (27, 28), therefore, they will be excluded from
the present review.
EFFECT OF FATTY ACIDS ON T-CELLS
Several studies have focused on the effect of fatty acids on T-cells.
Although these studies differ in experimental setting, especially
regarding the concentration of the fatty used, the type of T-cell
studied, and the T-cell stimulus, the overall data suggest that low
Table 1 | Examples of saturated, monounsaturated, and
polyunsaturated fatty acids that are most commonly used in
literature.
Type Isomer Name
Saturated 4:0 Butyric acid
12:0 Lauric acid
14:0 Myristic acid
16:0 Palmitic acid (PA)
18:0 Stearic acid (SA)
Monounsaturated 18:1 (ω9) Oleic acid (OA)
Polyunsaturated 18:2 (ω6) Linoleic acid (LA)
18:3 (ω3) Alpha-linolenic acid (ALA)
18:3 (ω6) Gamma-linolenic acid (GLA)
20:4 (ω6) Arachidonic acid (AA)
20:5 (ω3) Eicosapentaenoic acid (EPA)
22:5 (ω3) Docosapentaenoic acid (DPA)
22:6 (ω3) Docosahexaenoic acid (DHA)
concentrations of fatty acids can influence the proliferation of
T-cells, whereas higher concentrations induce apoptosis in a dose-
dependent manner, through the induction of several pathways
(29–34). In addition, the concentration at which apoptosis occurs
is also determined by the degree of saturation and the length of the
fatty acid. While short-chain fatty acids (SCFA) are not toxic even
at a concentration of 800µM or higher (30), longer, and more
unsaturated fatty acids can already be toxic in low concentrations
[e.g., linoleic acid (LA)] is toxic at 100µM (30–32).
In contrast to the apoptotic effects, the modulatory effects of
low, non-toxic concentrations of fatty acids on proliferation do
not seem to correlate with length of the fatty acids tested. There
are only a few studies studying the proliferation of T-cells after
incubation with fatty acids and they use different stimuli (29, 33,
35). While proliferation of anti-CD3/anti-CD4 stimulated T-cells
was not influenced by palmitic acid (PA) (29), concanavalin A
(ConA) stimulated T-cells proliferated less in the presence of PA
(33), indicating that fatty acids can have different effects depend-
ing on the stimulus used for T-cell activation. This is supported by
the fact that while proliferation of T-cells stimulated with ConA
was differentially affected by the saturated fatty acids stearic acid
(SA), and the unsaturated fatty acids oleic acid (OA) and LA (33),
stimulation with anti-CD3/anti-CD28 led to increased prolifera-
tion with all tested fatty acids [e.g., LA, SA, γ-linoleic acid (GLA),
PA, OA, and palmitoleic acid] independently of saturation degree
(35). Overall, the data indicate that different fatty acids can mod-
ulate proliferation of T-cells, although this is likely dependent on
the stimuli used.
Only a handful of studies have investigated cytokine produc-
tion by T-cells treated with fatty acids and they generally indicate
that fatty acids can modulate secretion of several cytokines, such
as TNFα, IL-6, IL8, IL1β, IL-2, IL10, and IFNγ (36–38). This mod-
ulation has been shown primarily for unsaturated fatty acids such
as OA and LA using T-cells activated by a polyclonal stimulus,
such as ionomycin (38) or ConA (37). The effect of saturated fatty
acids on cytokine secretion by activated T-cells is unclear. How-
ever, saturated fatty acids induced cytokine secretion in T-cells in
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the absence of T-cell activation in a dose-dependent manner (36),
while unsaturated fatty acids were unable to do so.
In conclusion, fatty acids are toxic to T-cells when administered
in high concentrations and can induce proliferation and cytokine
production when administered in non-toxic concentrations. The
effects of fatty acids on T-cell function seem to be dependent not
only on the saturation grade and length of fatty acids but also on
the T-cell stimulus used.
MECHANISMS BYWHICH FATTY ACID EXERT THEIR EFFECTS
How fatty acids exert their effects on different immune cells is
incompletely understood, despite the fact that several possible
mechanisms have been proposed. One possibility is that fatty acids
can diffuse through the membrane of T-cells in a passive process,
as some studies have shown that T-cells incorporate fatty acids in
their membrane upon exposure (38, 39).
In addition to this passive mechanism, there are several active
pathways possible, in general mediated by cellular receptors.
Among the receptors involved in the recognition of free fatty
acids, fatty acid transport proteins (FATPs) form a family of six
transmembrane proteins, with distinct tissue expression patterns
(40). FATPs are generally involved in the uptake of fatty acids,
although there are no studies regarding their expression in T-cells.
In addition to FATP, the fatty acid binding proteins (FABPs) are
a family of homologous cytoplasmic proteins with high affinity
for fatty acids. Even though FABPs are cytoplasmic proteins, it has
been suggested that these FABPs play a role in uptake, transport,
storage, and metabolism of fatty acids, with distinct patterns of
tissue expression (41, 42). Interestingly, one of these receptors, the
epidermal-FABP (FABP5) is also expressed on CD4+ T-cells (43).
Furthermore, a series of G protein-coupled receptors have been
recently identified,which recognize fatty acids with different affini-
ties and expression patterns. Five different receptors have been
identified that recognize extracellular fatty acids with different
lengths: free fatty acid receptor 1 (FFA1; GPR40) and GPR120 rec-
ognize long-chain fatty acids, GPR84 recognizes medium-chain
fatty acids, while SCFA are recognized by FFA2 (GPR43) and
FFA3 (GPR41) (44–46). The expression pattern of these receptors
on T-cells has been only partly investigated. These studies indi-
cated that FFA1 and FFA3 are not expressed on T-cells (47, 48),
while the medium-chain fatty acid receptor, GPR84, is expressed
by CD4+ and CD8+ cells although less abundantly than by mono-
cytes and neutrophils (49). Smith et al. recently showed that FFA2
is expressed on colonic regulatory T-cells (cTreg) (50).
In conclusion, several mechanisms could be involved in the
modulation of T-cells function by fatty acids; a passive mecha-
nism, in which the fatty acids diffuse through the membrane or
active mechanisms, in which FATPs, FABPs, or other receptors
could be involved. Their relative contribution to fatty acids uptake
awaits further investigation.
DOWNSTREAM EFFECTS OF FATTY ACIDS
There are several studies regarding downstream effects of fatty
acids. These studies focus mainly on the effects of OA, LA, or
PA on resting human T-cells (36) or Jurkat cells (T-cell leukemia
cell line) (31, 34, 37, 51, 52). As previously mentioned fatty
acids can influence T-cells in a dose-dependent manner, with low
doses modulating proliferation and higher doses inducing apop-
tosis. Treatment of T-cells with fatty acids induces neutral lipid
accumulation, such as triacylglycerol and cholesterol esters, and
incorporation of the fatty acids in phospholipids (31, 34, 37). The
induction of neutral lipid accumulation is mediated by activation
of insulin signaling pathways and glucose utilization, indicated
by elevated expression of insulin receptor and GLUT4 and by
increased glucose consumption and lactate production (34, 36).
It is believed that this pathway enables T-cells to evade the toxic
effects of fatty acids at both low and high concentrations. However,
when T-cells are exposed to too high concentrations, these mech-
anisms might not be sufficient to protect the cells from apoptosis
and these results in the induction of intrinsic apoptotic pathways
(31, 34, 37).
Several apoptotic characteristics are induced by fatty acids in
T-cells, such as mitochondrial depolarization (31, 34), caspase acti-
vation (34, 37), DNA fragmentation (31, 34), chromatin condensa-
tion (31), cytochrome c (34), and phosphatidylserine externaliza-
tion (31), indicating that T-cells treated with high-concentrations
fatty acids die due to apoptosis. In addition, T-cells incubated
with fatty acids also induce oxidative and nitrosative stress lead-
ing to apoptosis, indicated by higher levels of reactive oxygen
species (ROS), reactive nitrogen species, and lower levels of catalase
activity (34, 51, 52).
How these mechanisms would affect proliferation and cytokine
production of T-cells is unclear and awaits further investigation.
Likewise, it is unclear whether these mechanisms are still utilized
by T-cells that have been activated by their cognate antigen on
antigen-presenting cells and which display an increased energy
demand in order to proliferate, differentiate, and execute their
effector functions.
In conclusion, free fatty acids induce proliferation of resting
T-cells in low concentrations, while higher concentrations induce
apoptosis. In Figure 1, we present possible mechanisms involved
in the modulatory effects of fatty acids in T-cells.
IN VIVO RELEVANCE
As mentioned above, obese people express generally higher plasma
levels of free fatty acids after fasting when compared to healthy
controls. Likewise, the turnover rate of free fatty acids is higher
after fasting (14, 15). Furthermore, some studies indicated T-cell
numbers are decreased in obese persons (53–55) and T-cell pro-
liferation and T-cell subset composition are altered compared to
lean persons (54–57). The mechanisms underlying these differ-
ences between obese and lean individuals are unclear. However,
some studies addressing the effect of dietary fatty acid content
on the function of T-cells, both in rodent models (58–62) and
in humans (63, 64) suggest that fatty acids can be modulators of
T-cell function and phenotype also in vivo.
Rodent studies show that different high-fat diets can decrease
PHA (58) and conA (60) induced proliferation of T-cells when
compared to control diets. Furthermore, rodent models showed
that diets rich in fatty acids can have an effect on IL-2 produc-
tion and signaling, since IL-2 production (58) and the expression
of IL-2 receptor α-chain (CD25) (59) were increased when mice
or rats are fed fatty acid rich diets. More recently, some studies
investigated the effects of SCFAs on the immune system. SCFAs
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FIGURE 1 | Proposed mechanism through which free fatty acids exert
their effects onT-cells. Free fatty acids enter T-cells through currently
unknown mechanisms. Low concentrations of free fatty acids are
incorporated in phospholipids, while uptake of glucose sustains the
formation of triacylglycerol and cholesterol esters. In addition, low
concentrations of free fatty acids induce proliferation, cytokine production,
and lactate production by T-cells. However, when a T-cell encounters high
concentrations of free fatty acids this will lead to depolarization of the
mitochondrial membrane and the induction of intrinsic apoptotic pathways,
which eventually lead to apoptosis.
are metabolites of microbiota in the gut and are believed to play
an important role in the balance between pro-inflammatory and
anti-inflammatory effects in the gut. Indeed, recent studies show
that adding SCFAs, especially butyrate and propionate, to the diet
leads to induction of T-regulatory cells in the gut (61, 62). In
line with this, butyrate was shown to ameliorate T-cell-dependent
experimental colitis (61). In summary, these studies indicate that
fatty acids can affect T-cell proliferation, cytokine production, and
skewing in vivo.
There are only two studies regarding the effect of dietary change
of fatty acid content on the function of T-cells in humans (63, 64).
A diet containing MUFAs did not affect conA stimulated T-cell
proliferation (63), while another study using several diets with dif-
ferent fatty acids composition described a higher PHA and conA
induced proliferation of T-cells compared to baseline for most
diets investigated (64). A direct comparison of these studies is,
however, difficult due to differences in diet composition.
Overall, the data suggest that fatty acids can influence both
rodent and human T-cells in vivo. A firm conclusion is, however,
difficult to formulate, as rodent studies show decrease in prolif-
eration, while human studies either show unaffected proliferation
or induction of proliferation. Furthermore, it remains uncertain
whether the effects of saturated and unsaturated fatty acids are
different.
LIPID MEDIATORS
Lipid mediators are produced through conserved biosynthetic
pathways involving specific enzymes, which exert their function
on lipid precursors that are released from membranes. There are
several families of lipid mediators, which can be divided into pro-
inflammatory lipid mediators and the more recently described spe-
cialized pro-resolving lipid mediators (SPM). Pro-inflammatory
lipid mediators include prostaglandins and leukotrienes, while
SPM include lipoxins, resolvins, maresins, and protectins (23).
PRO-INFLAMMATORY LIPID MEDIATORS AND T-CELLS
Prostaglandins and their influence on T-cells are widely studied
and these studies have been reviewed elsewhere (65, 66). In short,
PGE2 is the most studied prostaglandin and it has been shown
to impair proliferative responses of T-cells (67–69). In addition,
PGE2 can affect T-cell cytokine production, whereby Th17 associ-
ated cytokines, such as IL17, are upregulated (70–73). Moreover,
PGE2 can change the Th1/Th2 balance by favoring Th2 skewing
in vitro and in a mice model (69, 74). The effect of PGE2 on skew-
ing of naïve T-cells toward Th17 cells is uncertain since there are
contradicting studies showing either an induction of Th17 cells
(75) or a reduction of Th17 cells (76), depending on the com-
bination of cytokines used to induce Th17 differentiation. PGE2
can exert these effects on T-cells through E-prostanoid (EP) 2
receptor and EP4, which are present on T-cells (72, 73, 75). So,
prostaglandins can affect T-cell proliferation and T-cell skewing
through the EP2 and EP4 receptors.
Another family of pro-inflammatory lipid mediators are the
leukotrienes, but the effects of leukotrienes on T-cells are not
completely known. A human study revealed that both Th1 and
Th2 express cysteinyl leukotriene receptor 1 (CYSLTR1) mRNA,
although expression of CYSLTR1 was higher in Th2 cells compared
to Th1 cells. In addition, activation of the CYSTLR1 with LTD4,
LTC4, or LTE4 led to the induction of calcium signaling in Th2
cells, but a much weaker response in Th1 cells. LTD4 can also act
as chemo attractant for Th2 cells (77). This indicates that Th2 cells
are more susceptible than Th1 cells to respond to leukotrienes.
Different in vivo mice models have indicated that mice defi-
cient in 5-lipoxygenase (5-LO), which is one of the key enzymes in
leukotriene production, have less T-cells infiltrating the inflamed
area (78–81), diminished numbers of CD4+CD25+ regulatory
T-cells, higher levels of IFNγ, and increased T-bet (Th1 lineage
commitment) (80). In addition, LTB4 dose dependently down-
regulates the differentiation of naïve T-cells into Tregs, while
it enhances the differentiation of Th17 cells, with more IL17
secretion and higher levels of RORγt mRNA expression (82).
In summary, pro-inflammatory lipid mediators seem to stim-
ulate T-cell migration (either directly or indirectly) and to favor
skewing toward Th2 or Th17 instead of Th1 or Tregs.
PRO-RESOLVING LIPID MEDIATORS AND T-CELLS
Pro-resolving lipid mediators were recently described and have
been shown to be involved in the resolution phase of inflam-
mation. There are only a few studies investigating the effects of
pro-resolving lipid mediators on T-cells; however, these studies
indicate that these lipid mediators can influence T-cells.
Lipoxins, especially lipoxin A4 (LXA4) and lipoxin B4 (LXB4),
have been shown to inhibit TNFα secretion from both PBMCs
and peripheral T-cells stimulated with anti-CD3 Abs (83), and the
effects observed with LXA4 were mediated by the LXA4 receptor
(FPR2/ALX), expressed on T-cells (83, 84). FPR2/ALX expression
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is higher on activated CD25+ and memory CD45RO+ CD4+
T-cells when compared to CD25− and naïve CD45RA+ CD4+
T-cells (84), indicating that activated T-cells can respond better to
the agonist of this receptor.
Administration of resolvin D1 (RvD1) led to reduced infiltra-
tion of CD4+ and CD8+ T-cells in the perivascular tissue of the
eye of LPS induced uveitis in rats, resulting in the amelioration of
the disease. This suggests that RvD1 prevents migration of T-cells
into the eye, either directly or indirectly, thereby preventing disease
in a rat model (85).
Moreover, protectin 1 (PD1) could reduce T-cell infiltration in
zymosan A induced peritonitis (86) and into the lungs of OVA-
sensitized and challenged mice (87). Furthermore, in vitro studies
show that PD1 inhibits cytokine secretion, such as TNFα and IFNγ
by T-cells and can induce apoptosis of T-cells (86). Therefore,
PD1 could influence the inflammatory response by preventing the
migration of T-cells and induction of apoptosis of T-cells.
In contrast to their pro-inflammatory counterparts, pro-
resolving lipid mediators appear to inhibit cytokine production
and migration of T-cells and to induce their apoptosis, thereby
promoting resolution of inflammation.
FUTURE RESEARCH PLANS
In this review, we have summarized the current knowledge on the
influence of fatty acids and lipid mediators on T-cells. These data
indicate that fatty acids and their derivatives do affect the func-
tion and phenotype of T-cells and that the type and concentration
of free fatty acids determines the outcome of this modulation
and most likely the outcome of T-cell-dependent immune reac-
tions. However, the presented data indicate that substantial further
research is needed as there are still several remaining questions that
need to be elucidated. These include a more detailed insight into
the mechanisms involved in fatty acid uptake and usage by the
cells, as well as into the possible in vivo impact of these changes.
Although some data exist on the effect of fatty acids on T-cell
proliferation and cytokine production, these are inconsistent due
to usage of different stimuli for T-cells. Future research should
probably focus on more physiological stimuli, including antigen-
specific stimulation using antigen-presenting cells. Moreover, the
molecular events linking fatty acid uptake to modification of
T-cell function and phenotype need to be identified, as they could
constitute drug targets for future therapies of obesity-linked com-
plications. Likewise, it is of interest whether stimulated cells use
the same mechanisms as unstimulated cells to evade the toxic
effects and the induction of proliferation and cytokines. Stim-
ulated cells have a different energy demand than unstimulated
cells, and therefore, could respond differently to fatty acids. This
would be directly relevant for understanding modulation of ongo-
ing immune responses by free fatty acids and consequently for
development of efficient vaccination strategies or efficient drugs
in T-cell-mediated diseases.
Additionally, in vivo studies systematically investigating the
effect of various dietary fatty acids on T-cells would be needed as
the current data are scarce and inconsistent. The latter is most likely
due to a lack of standardization in the diets and the outcome mea-
sures used in the published studies. Also, current research is mainly
focused on ω3 and ω6-rich diets, while relatively little is known
about other fatty acids, which are also abundant in diet, such as OA,
palmitic and palmitoleic acid, and others. Future research about
the effect of these fatty acids is needed.
Current knowledge regarding the effects of lipid mediators on
T-cells is mainly focused on pro-inflammatory lipid mediators.
Therefore, research both in vitro and in vivo addressing the effects
of pro-resolving lipid mediators on T-cell proliferation, differen-
tiation, and function would be of interest. This would not only
provide novel insights into the link between inflammation resolu-
tion and the adaptive immunity, which is a yet unexplored area of
research, but could also lead to identification of new drug targets
for modulation of T-cell responses.
CONCLUDING REMARKS
The Western world experiences an epidemic of obesity due to
excess intake of food. Among the many nutrients acquired in
excess, free fatty acids have an important impact on various bodily
functions, as recent research has made clear. In this review, we have
provided an overview of the current knowledge about the effects of
fatty acids and their derivatives on T-cells. The summarized data
indicate that the effect of fatty acids on T-cells is either stimulatory
or lipotoxic, depending on the capacity of the T-cells to evade the
toxic effects of the fatty acids. Both fatty acids and their oxidative
derivatives can influence T-cell proliferation, skewing, and differ-
entiation and this is usually dependent on the type of fatty acid.
This suggests that the type of fatty acid in the diet, rather than
its quantity, determine the outcome of an immune reaction in a
certain individual. Future research will teach us whether and how
fatty acids or lipid mediators can be used as drug targets in treating
obesity-related or T-cell-driven diseases.
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